Literature DB >> 6200784

Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).

C G Gottfries, R Adolfsson, S M Aquilonius, A Carlsson, S A Eckernäs, A Nordberg, L Oreland, L Svennerholm, A Wiberg, B Winblad.   

Abstract

In postmortem investigations of patients with dementia of Alzheimer type (AD/SDAT) (n = 14) the brain weight was significantly reduced when compared to controls (n = 16). In four AD/SDAT-brain parts investigated the concentrations of 5-hydroxy-tryptamine and noradrenaline were significantly reduced while 3-methoxy-4-hydroxyphenylglycol was significantly increased. In the caudate nucleus of the AD/SDAT-brains the concentrations of dopamine and homovanillic acid were significantly reduced. The activity of monoamine oxidase B was increased suggesting a proliferation of extra neuronal tissue in the AD/SDAT-brains. The activity of choline acetyl transferase was reduced in the four brain parts investigated, showing a general reduction in the acetylcholine system in the AD/SDAT-brains. The ganglioside concentration was significantly reduced suggesting a reduced density of nerve endings in the demented brains. The AD/SDAT-group was according to rating scales severely demented. Patients with an early onset of the dementia disease were more severely intellectually reduced and had more pronounced biochemical disturbances than those with a late onset of the dementia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6200784     DOI: 10.1016/0197-4580(83)90002-7

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  30 in total

1.  Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

Authors:  M D Galva; G P Bondiolotti; M Olasmaa; G B Picotti
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 2.  Mitochondrial function in ageing: coordination with signalling and transcriptional pathways.

Authors:  Fei Yin; Harsh Sancheti; Zhigang Liu; Enrique Cadenas
Journal:  J Physiol       Date:  2015-09-16       Impact factor: 5.182

3.  Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia.

Authors:  E D London; M J Ball; S B Waller
Journal:  Neurochem Res       Date:  1989-08       Impact factor: 3.996

4.  Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Authors:  S Hoyer; K Oesterreich; O Wagner
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

Review 5.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

6.  Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.

Authors:  Haroon Siddique; Linda S Hynan; Myron F Weiner
Journal:  J Clin Psychiatry       Date:  2009-05-05       Impact factor: 4.384

Review 7.  Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment.

Authors:  C G Gottfries
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 9.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

10.  Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a 13C-NMR study.

Authors:  Harsh Sancheti; Ishan Patil; Keiko Kanamori; Roberta Díaz Brinton; Wei Zhang; Ai-Ling Lin; Enrique Cadenas
Journal:  J Cereb Blood Flow Metab       Date:  2014-08-06       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.